




RealRate

MEDICINAL PRODUCTS 2019

Foamix Pharmaceuticals Ltd.
Rank 33 of 50





RealRate

MEDICINAL PRODUCTS 2019

Foamix Pharmaceuticals Ltd. Rank 33 of 50



The relative strengths and weaknesses of Foamix Pharmaceuticals Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Foamix Pharmaceuticals Ltd. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 205% points. The greatest weakness of Foamix Pharmaceuticals Ltd. is the variable Research and Development, reducing the Economic Capital Ratio by 95% points.

The company's Economic Capital Ratio, given in the ranking table, is 7.3%, being 13% points above the market average of -5.9%.

Input Variable	Value in 1000 USD
Assets, Current	101,167
Assets, Non-Current	2,564
General and Administrative Expense	14,013
Goodwill	0
Liabilities, Current	10,468
Liabilities, Non-Current	1,081
Other Assets	-2,235
Other Compr. Net Income	0
Other Expenses	212
Other Liabilities	0
Other Net Income	941
Other Revenues	3,595
Property, Plant and Equipment, Net	2,235
Research and Development	64,474

Output Variable	Value in 1000 USD
Liabilities	11,549
Assets	103,731
Expenses	78,699
Revenues	3,595
Stockholders Equity	92,182
Net Income	-74,163
Comprehensive Net Income	-74,163
Economic Capital Ratio	7.3%